GSK PLC (GSK)
36.97
+0.09
(+0.24%)
USD |
NYSE |
Nov 04, 16:00
37.01
+0.04
(+0.11%)
Pre-Market: 05:57
GSK Revenue (Quarterly): 10.43B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.43B |
| June 30, 2024 | 9.947B |
| March 31, 2024 | 9.339B |
| December 31, 2023 | 10.00B |
| September 30, 2023 | 10.32B |
| June 30, 2023 | 8.984B |
| March 31, 2023 | 8.449B |
| December 31, 2022 | 8.673B |
| September 30, 2022 | 9.214B |
| June 30, 2022 | 8.711B |
| March 31, 2022 | 9.647B |
| December 31, 2021 | 9.539B |
| September 30, 2021 | 9.137B |
| June 30, 2021 | 8.160B |
| March 31, 2021 | 10.23B |
| December 31, 2020 | -1.327B |
| September 30, 2020 | 11.17B |
| June 30, 2020 | 9.455B |
| March 31, 2020 | 11.65B |
| December 31, 2019 | 11.46B |
| September 30, 2019 | 11.56B |
| June 30, 2019 | 10.04B |
| March 31, 2019 | 9.980B |
| December 31, 2018 | 10.55B |
| September 30, 2018 | 10.54B |
| Date | Value |
|---|---|
| June 30, 2018 | 9.961B |
| March 31, 2018 | 10.04B |
| December 31, 2017 | 10.14B |
| September 30, 2017 | 10.27B |
| June 30, 2017 | 9.357B |
| March 31, 2017 | 9.145B |
| December 31, 2016 | 9.423B |
| September 30, 2016 | 9.907B |
| June 30, 2016 | 9.383B |
| March 31, 2016 | 8.917B |
| December 31, 2015 | 9.535B |
| September 30, 2015 | 9.494B |
| June 30, 2015 | 9.019B |
| March 31, 2015 | 8.522B |
| December 31, 2014 | 9.786B |
| September 30, 2014 | 9.426B |
| June 30, 2014 | 9.358B |
| March 31, 2014 | 9.287B |
| December 31, 2013 | 11.18B |
| September 30, 2013 | 10.09B |
| June 30, 2013 | 10.17B |
| March 31, 2013 | 10.05B |
| December 31, 2012 | 10.92B |
| September 30, 2012 | 10.31B |
| June 30, 2012 | 10.23B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.327B
Minimum
Dec 2020
11.65B
Maximum
Mar 2020
9.159B
Average
9.497B
Median
Revenue (Quarterly) Benchmarks
| AstraZeneca PLC | 12.94B |
| Pfizer Inc | 17.70B |
| Adaptimmune Therapeutics PLC | 128.23M |
| TC BioPharm (Holdings) PLC | -- |
| Moderna Inc | 221.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -75.47M |
| Total Expenses (Quarterly) | 10.18B |
| EPS Diluted (Quarterly) | -0.0364 |
| Enterprise Value | 91.88B |
| Gross Profit Margin (Quarterly) | 70.08% |
| Profit Margin (Quarterly) | -0.72% |
| Earnings Yield | 4.16% |
| Operating Earnings Yield | 7.44% |
| Normalized Earnings Yield | 4.877 |